These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 36087938)

  • 41. Protection Against the Omicron Variant Offered by Previous Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Retrospective Cohort Study.
    Rothberg MB; Kim P; Shrestha NK; Kojima L; Tereshchenko LG
    Clin Infect Dis; 2023 Feb; 76(3):e142-e147. PubMed ID: 35867678
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Frequency and risk of SARS-CoV-2 reinfections in Norway: a nation-wide study, February 2020 to January 2022.
    Bøås H; Storm ML; Tapia G; Kristoffersen AB; Løvlie AL; Størdal K; Lyngstad TM; Bragstad K; Hungnes O; Veneti L
    BMC Public Health; 2024 Jan; 24(1):181. PubMed ID: 38225588
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A case-case study on the effect of primary and booster immunization with China-produced COVID-19 vaccines on prevention of pneumonia and viral load among vaccinated persons infected by Delta and Omicron variants.
    Wu D; Ye Y; Tang L; Wang AB; Zhang R; Qian ZH; Wang FZ; Zheng H; Huang C; Lv XY; Wang HF; Zhang YY; Pan JJ; Li YF; Lu MX; Wang CS; Ma YT; An ZJ; Rodewald LE; Yin ZD; Wang XY; Wu ZY; Shao YM
    Emerg Microbes Infect; 2022 Dec; 11(1):1950-1958. PubMed ID: 35850623
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [COVID-19 recurrence due to reinfection with SARS-CoV-2 in a hemodialysis patient: there and back again].
    Vigotti FN; Bianco S; Alfieri V; Bilucaglia D; Motta D; Pignataro A; Timbaldi M; Torta E; Cesano G
    G Ital Nefrol; 2022 Apr; 39(2):. PubMed ID: 35471003
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vaccination Is Associated With Shorter Time to Target Cycle Threshold Value in Patients With SARS-CoV-2 Omicron Variant.
    Wu J; Wei Y; Shen F; Zhu S; Lu Y; Tian X; Zhang P
    Front Cell Infect Microbiol; 2022; 12():943407. PubMed ID: 35873164
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Characteristics and outcomes of vaccinated and nonvaccinated patients hospitalized in a single Italian hub for COVID-19 during the Delta and Omicron waves in Northern Italy.
    Rovida F; Esposito GL; Rissone M; Novelli V; Cutti S; Muzzi A; Rona C; Bertoli E; Daglio M; Piralla A; Paolucci S; Campanini G; Ferrari G; Giardina F; Zavaglio F; Lilleri D; Grugnetti AM; Grugnetti G; Odone A; Marena C; Baldanti F
    Int J Infect Dis; 2022 Sep; 122():420-426. PubMed ID: 35750265
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Risk of SARS-CoV-2 reinfections in children: a prospective national surveillance study between January, 2020, and July, 2021, in England.
    Mensah AA; Campbell H; Stowe J; Seghezzo G; Simmons R; Lacy J; Bukasa A; O'Boyle S; Ramsay ME; Brown K; Ladhani SN
    Lancet Child Adolesc Health; 2022 Jun; 6(6):384-392. PubMed ID: 35358491
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Incidence and outcome of SARS-CoV-2 reinfection in the pre-Omicron era: A global systematic review and meta-analysis.
    Ismail NF; Rahman AE; Kulkarni D; Zhu F; Wang X; Del Carmen Morales G; Srivastava A; Allen KE; Spinardi J; Kyaw MH; Nair H
    J Glob Health; 2023 Nov; 13():06051. PubMed ID: 37994839
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Risk Factors for Reinfection with SARS-CoV-2 Omicron Variant among Previously Infected Frontline Workers.
    Ellingson KD; Hollister J; Porter CJ; Khan SM; Feldstein LR; Naleway AL; Gaglani M; Caban-Martinez AJ; Tyner HL; Lowe AA; Olsho LEW; Meece J; Yoon SK; Mak J; Kuntz JL; Solle NS; Respet K; Baccam Z; Wesley MG; Thiese MS; Yoo YM; Odean MJ; Miiro FN; Pickett SL; Phillips AL; Grant L; Romine JK; Herring MK; Hegmann KT; Lamberte JM; Sokol B; Jovel KS; Thompson MG; Rivers P; Pilishvili T; Lutrick K; Burgess JL; Midgley CM; Fowlkes AL
    Emerg Infect Dis; 2023 Mar; 29(3):599-604. PubMed ID: 36703252
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 51. SARS-CoV-2 intra-host diversity, antibody response, and disease severity after reinfection by the variant of concern Gamma in Brazil.
    Naveca FG; Nascimento VA; Nascimento F; Ogrzewalska M; Pauvolid-Corrêa A; Araújo MF; Arantes I; Batista ÉR; Magalhães AÁ; Vinhal F; Mattos TP; Riediger I; Debur MDC; Grinsztejn B; Veloso VG; Brasil P; Rodrigues RR; Rovaris DB; Fernandes SB; Fernandes C; Santos JHA; Abdalla LF; Costa-Filho R; Silva M; Souza V; Costa ÁA; Mejía M; Brandão MJ; Gonçalves LF; Silva GA; de Jesus MS; Pessoa K; Corado ALG; Duarte DCG; Machado AB; Zukeram KA; Valente N; Lopes RS; Pereira EC; Appolinario LR; Rocha AS; Tort LFL; Sekizuka T; Itokawa K; Hashino M; Kuroda M; Dezordi FZ; Wallau GL; Delatorre E; Gräf T; Siqueira MM; Bello G; Resende PC
    Sci Rep; 2023 May; 13(1):7306. PubMed ID: 37147348
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effectiveness of the BNT162b2 Vaccine after Recovery from Covid-19.
    Hammerman A; Sergienko R; Friger M; Beckenstein T; Peretz A; Netzer D; Yaron S; Arbel R
    N Engl J Med; 2022 Mar; 386(13):1221-1229. PubMed ID: 35172072
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection.
    Gallais F; Gantner P; Bruel T; Velay A; Planas D; Wendling MJ; Bayer S; Solis M; Laugel E; Reix N; Schneider A; Glady L; Panaget B; Collongues N; Partisani M; Lessinger JM; Fontanet A; Rey D; Hansmann Y; Kling-Pillitteri L; Schwartz O; De Sèze J; Meyer N; Gonzalez M; Schmidt-Mutter C; Fafi-Kremer S
    EBioMedicine; 2021 Sep; 71():103561. PubMed ID: 34455390
    [TBL] [Abstract][Full Text] [Related]  

  • 54. COVID-19 infection among healthcare workers in an oncology hospital.
    İskender G; Mert D; Avşar Z; Kölgelier S; Ertek M
    J Infect Dev Ctries; 2023 Sep; 17(9):1246-1254. PubMed ID: 37824361
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effectiveness of the booster dose of COVID-19 vaccine in the Basque Country during the sixth wave: A nationwide cohort study.
    Arrospide A; Sagardui MG; Larizgoitia I; Iturralde A; Moreda A; Mar J
    Vaccine; 2023 Jun; 41(29):4274-4279. PubMed ID: 37271704
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines.
    Lu L; Chen LL; Zhang RR; Tsang OT; Chan JM; Tam AR; Leung WS; Chik TS; Lau DP; Choi CY; Fong CH; Cai JP; Tsoi HW; Choi CY; Zhang X; Abdullah SMU; Chan BP; Chan KH; Yuen KY; Hung IF; To KK
    EBioMedicine; 2022 May; 79():103986. PubMed ID: 35398786
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Disease and social factors associated with healthcare utilization for the treatment of SARS-CoV-2 infections in a longitudinal cohort of essential workers in Arizona.
    Rivers P; Jovel K; Ramadan F; Barnett JJA; Ellingson KD; Burgess JL; Lutrick K
    BMC Health Serv Res; 2023 Oct; 23(1):1118. PubMed ID: 37853403
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Risk and severity of SARS-CoV-2 reinfections during 2020-2022 in Vojvodina, Serbia: A population-level observational study.
    Medić S; Anastassopoulou C; Lozanov-Crvenković Z; Vuković V; Dragnić N; Petrović V; Ristić M; Pustahija T; Gojković Z; Tsakris A; Ioannidis JPA
    Lancet Reg Health Eur; 2022 Sep; 20():100453. PubMed ID: 35791336
    [TBL] [Abstract][Full Text] [Related]  

  • 59. SARS-CoV-2 Reinfection and Severity of the Disease: A Systematic Review and Meta-Analysis.
    Nguyen NN; Nguyen YN; Hoang VT; Million M; Gautret P
    Viruses; 2023 Apr; 15(4):. PubMed ID: 37112949
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Incidence of Omicron Variant Reinfection and Reduction of Reinfection Risk After Coronavirus Disease 2019 Vaccination in Children.
    Ikuse T; Aizawa Y; Hasegawa S; Takahashi M; Hayashi T; Kon M; Tamura T; Matsumoto H; Saitoh A
    J Pediatric Infect Dis Soc; 2023 Dec; 12(12):634-637. PubMed ID: 37936292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.